Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$180.56M$180.56M+50.3% vs Q3 2022 Net Income$49.22M$49.22M+210.1% vs Q3 2022 EPS Diluted$0.91$0.91+203.3% vs Q3 2022 Gross Profit$108,403,000+85.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$64,334,000+215.7% Free Cash Flowderived$54,141,000+267.0% Margins · derivedGross margin60.0%+11.3 pt vs Q3 2022
Operating margin40.3%+20.9 pt vs Q3 2022
Net margin27.3%+14.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end